🇺🇸 ClinicalTrials.govClinicalTrials.gov · 试验状态变更Doubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·源无时间·以抓取为准·⟳ 抓取 20:16:02·⚡ 决策 10-13 20:18:57 +2m55s·14.1 天前
赛诺菲SAR441566克罗恩病II期试验（NCT06637631）登记页状态更新，但正文仅为常规方案描述、无任何临床数据或里程碑事件
推送正文只是临床试验登记记录的标准方案文本，不含任何疗效/安全性数据、监管节点或状态迁移的具体说明；赛诺菲为超大市值药企，SAR441566尚处II期，此类登记页行政性更新对公司基本面与股价无实质影响，无方向、无edge、无交易价值。
📄 原文ClinicalTrials.gov · 试验状态变更↗ 原文
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to eval…
不做 赛诺菲 Sanofi（ADR）（SNY.US）
信号仅为SAR441566（NCT06637631）克罗恩病II期试验的ClinicalTrials.gov登记页常规更新，正文无任何临床数据、状态迁移明细或监管里程碑；对超大市值药企赛诺菲无收入/估值影响，无方向与edge，不交易。未来真正的II期数据读出属独立催化，需另行研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是一条ClinicalTrials.gov的常规登记/状态维护推送（NCT06637631，赛诺菲SAR441566克罗恩病II期），正文无任何临床读出或里程碑，对千亿级市值的赛诺菲不构成可交易催化，回避。
消息传播链
- 政府官方登记库推送NCT06637631状态/记录更新，但抓取正文仅含标准研究方案描述，未标注具体迁移字段，无数据或里程碑
主要风险
- 若本次状态实际对应招募完成且后续临近II期数据读出，可能在未来成为独立催化，但当前推送本身不含该信息，不据此交易
- 档案事件时点缺少created_ms、且未给出变更字段明细，无法排除存在未被正文捕获的状态变化，需以ClinicalTrials.gov历史记录原件为准
反向证据
- 做多前查反向 · 来源 web · 影响 none
未检索到任何SAR441566克罗恩病II期疗效/安全性数据或正面读出，本次推送不含可做多的surprise
检索:SAR441566 phase 2 Crohn data readout positive results 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未据此交易；早期管线资产的纯登记更新对超大市值药企无edge，确认AVOID
方向:无可供定价的事件方向：临床试验登记页的行政性状态维护（无数据读出）历史上不产生系统性股价反应，不属于需要先例校准的催化类型
涨幅量级:无ENTER标的，不校准幅度
形态:不适用
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`sar441566 crohn's disease phase 2 nct06637631 status change | sar441566 dose ranging moderate severe crohn induction maintenance trial | 赛诺菲 sar441566 克罗恩病 ii期 临床试验状态`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召 - web_search 成功 doubao_search · 2,039 ms
豆包搜索结果（原始查询:SAR441566 NCT06637631 phase 2 Crohn's disease Sanofi first patient status；API SearchType:web）
原文全文
展开原文 · 1,055 字
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD.
This study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (LTS) study. The MS period includes a Double-Blind (DB) treatment period with 12 weeks of induction followed by 40 weeks of maintenance.
Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. The combined duration of the DB maintenance and OL periods cannot exceed 40 weeks, depending on when participants switch.
This study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (LTS) study. The MS period includes a Double-Blind (DB) treatment period with 12 weeks of induction followed by 40 weeks of maintenance.
Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. The combined duration of the DB maintenance and OL periods cannot exceed 40 weeks, depending on when participants switch.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b0beae6d12· 2026-10-13 20:18 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前